Salama HA, Mahmoud AA, Kamel AO, Abdel Hady M, Awad GA
Routine monitoring, honest dialogue with your doctor, and early reporting of symptoms all assist in making retatrutide use safe
La tirzepatida (15 mg una vez a la semana), un agonista dual que acta sobre los receptores GLP-1 y GIP, produjo una prdida de peso de hasta el 17,8% despus de 72 semanas , y la semaglutida (2,4 mg una vez a la semana) produjo una prdida de peso de hasta el 13,9% despus de 68 semanas, ambas en comparacin con placebo
However, because it remains active in the body for up to a week , appetite suppression and metabolic benefits remain consistent throughout the entire dosing cycle
Current and emerging therapeutic targets for IBD
L., Sarvet, A